Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
Jaguar Health (NASDAQ:JAGX) plans to file its Form 10-Q earnings report for the quarter ended June 30, 2026 on August 19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) plans to file its Form 10-Q earnings report for the quarter ended June 30, 2026 on August 19, 2026. The company will host an investor webcast the same day at 4:30 p.m. Eastern to review Q2 2026 financials and provide corporate updates.
A replay of the webcast will be available in the investor relations section of Jaguar Health’s website. Jaguar and its family companies Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences focus on plant-derived prescription drugs for complicated gastrointestinal and mental health indications.
Details
Market move: JAGX +11.10% in the Aug 18 session. Q2 2026 earnings report
On Aug 18, the day this news came out, JAGX closed 11.10% above the previous close. Argus tracked a peak move of +24.8% during that session. Our momentum scanner recorded 14 alerts for this stock that day. Relative volume reached 1.9x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 18 session.
Key Figures
- Reporting quarter
- Q2 2026
- Financials to be reviewed during the webcast
- Form 10-Q filing date
- August 19, 2026
- Quarterly report filing
- Quarter end
- June 30, 2026
- Quarter covered by the Form 10-Q
- Webcast time
- 4:30 p.m. Eastern
- August 19, 2026 investor webcast
Previous Earnings Reports
-
Revenue growth and narrowed loss were followed by a negative 24-hour reaction.
-
Webcast scheduling and Form 10-Q filing notice preceded a positive reaction.
-
Higher sequential revenue and continued losses preceded a positive reaction.
-
Form 10-Q filing and webcast scheduling notice preceded a positive reaction.
-
Revenue growth and wider losses were followed by a negative 24-hour reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 10-q regulatory
intestinal failure medical
microvillus inclusion disease medical
short bowel syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026
SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates.
Participation Instructions for Jaguar Health Investor Webcast
When: Wednesday, August 19, 2026 at 4:30 p.m. Eastern
Participant Registration & Access Link: Click Here
Replay: A replay of the webcast will be available on the investor relations section of Jaguar's website: (click here)
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will file its Form 10-Q on August 19, 2026 for the quarter ended June 30, 2026, and the expectation that Jaguar will hold an investor webcast on August 19, 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.